XML 51 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Aug. 31, 2020
Mar. 31, 2020
Aug. 31, 2018
May 31, 2018
Sep. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Other Commitments [Line Items]                        
Obligation expiration year                 2021      
Gain (loss) on strategic investment                 $ (1,262) $ 506    
Restricted cash         $ 5,770   $ 4,787   5,770 4,787 $ 4,787 $ 4,826
Letter of Credit | Corporate Credit Card Program                        
Other Commitments [Line Items]                        
Restricted cash         2,000       2,000      
Letter of Credit | Fleet Program                        
Other Commitments [Line Items]                        
Restricted cash         400       400      
Other assets                        
Other Commitments [Line Items]                        
Aggregate carrying amount of strategic equity investment         1,000       1,000   $ 2,300  
Other expense                        
Other Commitments [Line Items]                        
Gain (loss) on strategic investment         (200)   $ 700   (1,300) $ 500    
Cersci Therapeutics                        
Other Commitments [Line Items]                        
Upfront consideration and transaction costs $ 52,800                      
Non-cash upfront payment $ 44,300                      
Upfront payment conditions The Company incurred an aggregate of $52.8 million in upfront consideration and transaction costs, of which, $44.3 million was paid through the issuance of approximately 1.2 million shares of the Company’s common stock.                      
Common stock issuance 1,200,000                      
Cersci Therapeutics | Research and development                        
Other Commitments [Line Items]                        
Assets acquisition and upfront payment                 $ 45,700      
Exclusivity Deed | Neuren                        
Other Commitments [Line Items]                        
Aggregate carrying amount of strategic equity investment       $ 3,100                
Shares subscribed       1,330,000                
Exclusivity Deed | Neuren | Selling, general and administrative                        
Other Commitments [Line Items]                        
Payments for exclusive right       $ 900                
License Agreements | Neuren | North America                        
Other Commitments [Line Items]                        
Upfront license fee   $ 10,000 $ 10,000                  
License Agreements | Neuren | Research and development | North America                        
Other Commitments [Line Items]                        
Upfront payment           $ 10,000   $ 10,000        
Maximum                        
Other Commitments [Line Items]                        
Percentage of royalty payments obligation on net product sales                 2.00%      
Mile stone payments payable         $ 2,000,000       $ 2,000,000      
Maximum | Cersci Therapeutics | Development Commercialization and Sales Milestones                        
Other Commitments [Line Items]                        
Compensation expense related to mergers to former holders $ 887,000                      
Maximum | License Agreements | Neuren | North America                        
Other Commitments [Line Items]                        
Mile stone payments payable   $ 515,000 $ 455,000     $ 515,000